RISK FACTORS FOR ANASTOMOTIC LEAKAGE FOLLOWING TOTAL OR SUBTOTAL COLECTOMY (RIALTCOT)
Launched by HOSPITAL UNIVERSITARIO RAMON Y CAJAL · Aug 12, 2020
Trial Information
Current as of April 30, 2025
Unknown status
Keywords
ClinConnect Summary
Ileorectal (IRA) or ileosigmoid anastomosis (ISA) following Total or Subtotal Colectomy (TSC) are frequently performed in inflammatory bowel disease (IBD) (Crohn´s disease, ulcerative colitis and indeterminate colitis), familiar adenomatous polyposis or colonic polyposis syndromes and colorectal cancer (CRC). TSC is less frequently performed in refractory constipation and ischemic colitis.
Anastomotic leakage (AL) is a significant complication associate with increased mortality, reoperation and derivative morbidity and is also related to poor long term outcomes in oncological resections. A...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • (1) over 18 years old
- • (2) underwent restorative TSC with ISA or IRA anastomosis (emergent or elective)
- • (3) with/without loop ileostomy
- • (4) between 2013-2019
- Exclusion Criteria:
- • (1) non-restorative TSC
- • (2) previous colorectal resection
- • (3) deferred anastomosis in trauma surgery and
- • (4) other surgical resection in the same procedure.
About Hospital Universitario Ramon Y Cajal
Hospital Universitario Ramón y Cajal, located in Madrid, Spain, is a leading academic medical center recognized for its commitment to innovative research and high-quality patient care. As a prominent institution affiliated with the University of Alcalá, it combines clinical excellence with a robust research agenda, fostering advancements in medical science through rigorous clinical trials. The hospital is dedicated to enhancing patient outcomes and contributing to the global medical community by exploring new therapeutic approaches and healthcare solutions across various specialties.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Patients applied
Trial Officials
Juan Ocaña, MD
Principal Investigator
H.U Ramon y Cajal
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials